Stella Diagnostics (Stella Diagnostics) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Days Payable?

Stella Diagnostics's average Accounts Payable for the three months ended in Sep. 2023 was $0.15 Mil. Stella Diagnostics's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Stella Diagnostics's Days Payable or its related term are showing as below:

SLDX's Days Payable is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 67.81
* Ranked among companies with meaningful Days Payable only.

Stella Diagnostics's Days Payable stayed the same from . 20 (0.00) to Sep. 2023 (0.00). stayed the same

Stella Diagnostics Days Payable Historical Data

The historical data trend for Stella Diagnostics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Days Payable Chart

Stella Diagnostics Annual Data

Trend

Days Payable

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Days Payable	-	-

Competitive Comparison of Stella Diagnostics's Days Payable

For the Diagnostics & Research subindustry, Stella Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's Days Payable distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's Days Payable falls into.

Stella Diagnostics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Stella Diagnostics's Days Payable for the fiscal year that ended in . 20 is calculated as

	Days Payable (A: . 20 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: . 20 )	+	Accounts Payable (A: . 20 ))	/	count )	/	Cost of Goods Sold (A: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365
=	0					/		*	365
=	N/A

Stella Diagnostics's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2022 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0	+	0.145)	/	1 )	/	0	*	365 / 4
=	0.145					/	0	*	365 / 4
=	N/A

Stella Diagnostics Days Payable Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.